Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn’s disease patients

References

• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485–489.
   PubMed Web of Science ®Google Scholar
• Roberts RL, Barclay ML. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16:891–903.
   PubMed Web of Science ®Google Scholar
• Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol. 2011;17:4166–4173.
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28–62.
   PubMed Web of Science ®Google Scholar
• Wu J, Gao Y, Yang C, et al. Low-dose azathioprine is effective in maintaining remission among Chinese patients with Crohn's disease. J Transl Med. 2013;11:235.
   PubMed Web of Science ®Google Scholar
• Lee MN, Kang B, Choi SY, et al. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis. 2015;21:1054–1062.
   PubMed Web of Science ®Google Scholar
• Ohtsuka Y, Arai K, Aoyagi Y, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease. J Gastroenterol Hepatol. 2010;25:1626–1630.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047–1053.
   PubMed Web of Science ®Google Scholar
• Andoh A, Tsujikawa T, Ban H, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2008;23:1373–1377.
   PubMed Web of Science ®Google Scholar
• Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1301–1307.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Choe YH. Monitoring and safety of azathioprine therapy in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr. 2013;16:65–70.
   PubMedGoogle Scholar
• Dassopoulos T, Dubinsky MC, Bentsen JL, et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn’s disease. Aliment Pharmacol Ther. 2014;39:163–175.
   PubMed Web of Science ®Google Scholar
• Reinshagen M, Schütz E, Armstrong VW, et al. 6-Thioguanine nucleotide–adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized controlled, open trial. Clin Chem. 2007;53:1306–1314.
   PubMed Web of Science ®Google Scholar
• LeLeiko NS, Lobato D, Hagin S, et al. 6-Thioguanine levels in pediatric IBD patients: adherence is more important than dose. Inflamm Bowel Dis. 2013;19:2652–2658.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6, 16–19.
   PubMedGoogle Scholar
• Xia Q, Huang Y, Wang YY, et al. Clinical application of monitoring thiopurine methyltransferase gene polymorphism and 6-thioguanine nucleotides concentration in red blood cells on inflammatory bowel disease patients with azathioprine treatment. Chin J Clin Pharmacol Ther. 2014;19:302–308. (in Chinese).
   Google Scholar
• Lee KM, Kim YS, Seo GS, et al. IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of thiopurines in inflammatory bowel disease: a Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13:193–207.
   PubMed Web of Science ®Google Scholar
• Yu LF, Zhong J, Cheng SD, et al. Low-dose azathioprine effectively improves mucosal healing in Chinese patients with small bowel Crohn's disease. J Dig Dis. 2014;15:180–187.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhong J, Wang Z, et al. The efficacy of medium and long-term immunosuppressive therapy in Crohn’s disease. Chin J Dig. 2012;32:312–315. (in Chinese).
   Google Scholar
• Kim MJ, Lee SY, Choe YH. Monitoring thiopurine metabolites in Korean pediatric patients with inflammatory bowel disease. Yonsei Med J. 2014;55:1289–1296.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13:1118–1124.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–713.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Battat R, Benmassaoud A, et al. Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD. Dig Dis Sci. 2015;60:478–484.
   PubMed Web of Science ®Google Scholar
• Odahara S, Uchiyama K, Kubota T, Ito Z, Takami S, Kobayashi H, et al. A prospective study evaluating metabolic capacity of thiopurine and associated adverse reactions in Japanese Patients with Inflammatory Bowel Disease (IBD). PLoS One. 2015;10:e0137798.
   PubMed Web of Science ®Google Scholar